Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.48 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | IDH2 | P48735 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443102 | 0.86 | PARP1 (0.44) | — | |
| SCHEMBL4135603 | 0.85 | FASN (0.47) | CKS1BSKP1SKP2HPGD | |
| SCHEMBL31078190 | 0.78 | NCF1 (0.56) | CKS1BSKP1SKP2GBA1 | |
| SCHEMBL23362298 | 0.78 | NCF1 (0.56) | CKS1BSKP1SKP2GBA1 | |
| SCHEMBL23362072 | 0.78 | NCF1 (0.56) | CKS1BSKP1SKP2GBA1 | |
| SCHEMBL23362074 | 0.78 | NCF1 (0.56) | CKS1BSKP1SKP2GBA1 | |
| SCHEMBL5788417 | 0.78 | HPGDS (0.52) | USP30CKS1BSKP1SKP2HPGDS | |
| SCHEMBL3774377 | 0.77 | DNMT3A (0.49) | GBA1IDH1IDH2 | |
| SCHEMBL30061177 | 0.77 | GBA1 (0.54) | SFRP1CKS1BSKP1SKP2HPGDS | |
| SCHEMBL23363311 | 0.76 | MAPT (0.52) | USP30SFRP1CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-20 | — | — | US | claimed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | claimed |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2527330-A1 | Inhibitors of the hedgehog pathway | Exelixis, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2134695-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | Exelixis, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | SHH, GLI1, SMO | USP30 2012/4885SFRP1 29/4885CKS1B 480/4885 |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | SHH, GLI1, SMO | USP30 1991/4885SFRP1 31/4885CKS1B 463/4885 |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | TP53, ANXA5, VHL | USP30 1568/4885SFRP1 3478/4885CKS1B 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.